An increase in the risk of developing RPF has also been demonstrated for the new drug class used in the personalised therapy of lung cancer or melanoma-anti-programmed cell death 1 (anti-PD-1) antibodies [100]. This evidence concerns the gene PDCD1 and lung carcinoma.